CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.

Karim Fizazi,Pablo Gonzalez-Mella,Daniel Castellano,J.N. Minatta,Arash Rezazadeh,David R. Shaffer,Juan Carlos Vázquez-Limón,Héctor Manuel Sánchez López,Andrew J. Armstrong,Lisa G. Horvath,Carlos Dzik,Neha P. Amin,Jia Li,Keziban Unsal-Kacmaz,Margitta Retz,Fred Saad,Daniel P. Petrylak,Russell K. Pachynski

CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.

2021

Karim Fizazi
Pablo Gonzalez-Mella
Daniel Castellano
J.N. Minatta
Arash Rezazadeh
David R. Shaffer
Juan Carlos Vázquez-Limón
Héctor Manuel Sánchez López
Andrew J. Armstrong
Lisa G. Horvath
Carlos Dzik
Neha P. Amin
Jia Li
Keziban Unsal-Kacmaz
Margitta Retz
Fred Saad
Daniel P. Petrylak
Russell K. Pachynski

12Background: CheckMate 9KD (NCT03338790) is a phase 2 trial of nivolumab (NIVO; anti-PD-1) in combination with rucaparib, docetaxel (DOCE), or enzalutamide for patients with metastatic castration-...

Keywords:

Prostate cancer
Castration
Oncology
Rucaparib
Docetaxel
castration resistant
Checkmate
Nivolumab
Enzalutamide
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations